Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement

被引：21
|
作者：
Nahi, Hareth [1 ]
Svedmyr, Erik [1 ]
Lerner, Richard [1 ]
机构：
[1] Karolinska Inst, Dept Med, Stockholm, Sweden
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2014年 / 92卷 / 05期
关键词：
THERAPY; AGENTS;
D O I：
10.1111/ejh.12247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：454 / 455
页数：2
相关论文
共 46 条
  • [21] Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
    Tabchi, Samer
    Nair, Rajit
    Kunacheewa, Chutima
    Patel, Krina K.
    Lee, Hans C.
    Thomas, Sheeba K.
    Amini, Behrang
    Ahmed, Sairah
    Mehta, Rohtesh S.
    Bashir, Qaiser
    Qazilbash, Muzzaffar H.
    Weber, Donna M.
    Orlowski, Robert Z.
    Alexanian, Raymond
    Feng, Lei
    Manasanch, Elisabet E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09) : 560 - 569
  • [22] Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate-to high-dose methotrexate
    Zajac-Spychala, Olga
    Pawlak, Mikolaj
    Karmelita-Katulska, Katarzyna
    Pilarczyk, Jakub
    Jonczyk-Potoczna, Katarzyna
    Przepiora, Agnieszka
    Derwich, Katarzyna
    Wachowiak, Jacek
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2342 - 2351
  • [23] A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Biran, Noa
    Rowley, Scott D.
    Vesole, David H.
    Zhang, Shijia
    Donato, Michele L.
    Skarbnik, Alan P.
    Richter, Joshua
    Pecora, Andrew
    Siegel, David S.
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1881 - 1891
  • [24] Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan C.
    Abbas, Mohammad
    Dai, Lijun
    Pregja, Silvana Lalo
    Burt, Steve
    Boyiadzis, Michael
    Roodman, G. David
    Mapara, Markus Y.
    Agha, Mounzer
    Waas, John
    Shuai, Yongli
    Normolle, Daniel
    Zonder, Jeffrey A.
    BLOOD, 2012, 119 (20) : 4608 - 4613
  • [25] Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease
    Mitsunobu, Takuro
    Nishikawa, Takuro
    Kusuda, Masaki
    Nakagawa, Shunsuke
    Kodama, Yuichi
    Okamoto, Yasuhiro
    Kawano, Yoshifumi
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (06) : E456 - E458
  • [26] Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
    Sung, Kang Hyun
    Lee, Eun Hee
    Kim, Young Zoon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (04) : 551 - 560
  • [27] Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study
    Nakasu, Yoko
    Mitsuya, Koichi
    Hayashi, Nakamasa
    Okamura, Ikue
    Mori, Keita
    Enami, Terukazu
    Tatara, Raine
    Nakasu, Satoshi
    Ikeda, Takashi
    SPRINGERPLUS, 2016, 5
  • [28] Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
    Girnius, Saulius
    Seldin, David C.
    Skinner, Martha
    Finn, Kathleen T.
    Quillen, Karen
    Doros, Gheorghe
    Sanchorawala, Vaishali
    ANNALS OF HEMATOLOGY, 2010, 89 (06) : 579 - 584
  • [29] Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma
    Gang, A. O.
    Arpi, M.
    Gang, Uffe J. O.
    Vangsted, A. J.
    HEMATOLOGY, 2010, 15 (04) : 222 - 229
  • [30] Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
    Park, Jun Su
    Lim, Do Hoon
    Ahn, Yong Chan
    Park, Won
    Kim, Seok Jin
    Kim, Won Seog
    Kim, Kihyun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (11) : 995 - 1001
12345